Top

Published in:

Open Access 01-06-2012 | Original article

The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression

Authors: Caroline Schroten, Natasja F. Dits, Ewout W. Steyerberg, Ries Kranse, Arno G. J. L. H. van Leenders, Chris H. Bangma, Robert Kraaij

Published in: Cancer Immunology, Immunotherapy | Issue 6/2012

Abstract

Background

Given the fact that prostate cancer incidence will increase in the coming years, new prognostic biomarkers are needed with regard to the biological aggressiveness of the prostate cancer diagnosed. Since cytokines have been associated with the biology of cancer and its prognosis, we determined whether transforming growth factor beta 1 (TGFβ1), interleukin-7 (IL-7) receptor and IL-7 levels add additional prognostic information with regard to prostate cancer-specific survival.

Materials and methods

Retrospective survival analysis of forty-four prostate cancer patients, that underwent radical prostatectomy, was performed (1989–2001). Age, Gleason score and pre-treatment PSA levels were collected. IL-7, IL-7 receptor and TGFβ1 levels in prostate cancer tissue were determined by quantitative real-time RT-PCR and their additional prognostic value analyzed with regard to prostate cancer survival. Hazard ratios and their confidence intervals were estimated, and Akaike’s information criterion was calculated for model comparison.

Results

The predictive ability of a model for prostate cancer survival more than doubled when TGFβ1 and IL-7 were added to a model containing only the Gleason score and pre-treatment PSA (AIC: 18.1 and AIC: 6.5, respectively).

Conclusion

IL-7 and TGFβ1 are promising markers to indicate those at risk for poor prostate cancer survival. This additional information may be of interest with regard to the biological aggressiveness of the diagnosed prostate cancer, especially for those patients screened for prostate cancer and their considered therapy.

Eckersberger E, Finkelstein J, Sadri H, Margreiter M, Taneja SS, Lepor H, Djavan B (2009) Screening for prostate cancer: A review of the ERSPC and PLCO trials. Rev Urol 11:127–133PubMed

Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320–1328PubMedCrossRef

Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemother Rep 50:125–128PubMed

Pinthus JH, Witkos M, Fleshner NE, Sweet J, Evans A, Jewett MA, Krahn M, Alibhai S, Trachtenberg J (2006) Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol 176:979–984; discussion 984

Rajinikanth A, Manoharan M, Soloway CT, Civantos FJ, Soloway MS (2008) Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years. Urology 72:177–182PubMedCrossRef

Allam CK, Bostwick DG, Hayes JA, Upton MP, Wade GG, Domanowski GF, Klein MA, Boling EA, Stilmant MM (1996) Interobserver variability in the diagnosis of high-grade prostatic intraepithelial neoplasia and adenocarcinoma. Mod Pathol 9:742–751PubMed

Descazeaud A, Rubin MA, Allory Y, Burchardt M, Salomon L, Chopin D, Abbou C, de la Taille A (2005) What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer? Eur Urol 48:911–915PubMedCrossRef

Tsivian M, Sun L, Mouraviev V, Madden JF, Mayes JM, Moul JW, Polascik TJ (2009) Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology 74:1090–1093PubMedCrossRef

Orozco R, O’Dowd G, Kunnel B, Miller MC, Veltri RW (1998) Observations on pathology trends in 62, 537 prostate biopsies obtained from urology private practices in the United States. Urology 51:186–195PubMedCrossRef

10.

Muntener M, Epstein JI, Hernandez DJ, Gonzalgo ML, Mangold L, Humphreys E, Walsh PC, Partin AW, Nielsen ME (2008) Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 53:767–775; discussion 775-766

11.

Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Sebo TJ, Blute ML (2009) The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. J Urol 181:95–104; discussion 104

12.

Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW (1995) Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45:542–549PubMedCrossRef

13.

Wise GJ, Marella VK, Talluri G, Shirazian D (2000) Cytokine variations in patients with hormone treated prostate cancer. J Urol 164:722–725PubMedCrossRef

14.

Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC (1999) Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 161:182–187PubMedCrossRef

15.

Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH (1992) Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl 16H:54–61PubMedCrossRef

16.

Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC (1993) Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol 24:4–9PubMedCrossRef

17.

Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC (1995) Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73:628–635PubMed

18.

Perry KT, Anthony CT, Steiner MS (1997) Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate. Prostate 33:133–140PubMedCrossRef

19.

Tang J, Nuccie BL, Ritterman I, Liesveld JL, Abboud CN, Ryan DH (1997) TGF-beta down-regulates stromal IL-7 secretion and inhibits proliferation of human B cell precursors. J Immunol 159:117–125PubMed

20.

Dubinett SM, Huang M, Dhanani S, Economou JS, Wang J, Lee P, Sharma S, Dougherty GJ, McBride WH (1995) Down-regulation of murine fibrosarcoma transforming growth factor-beta 1 expression by interleukin 7. J Natl Cancer Inst 87:593–597PubMedCrossRef

21.

Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342:1350–1358PubMedCrossRef

22.

Jicha DL, Mule JJ, Rosenberg SA (1991) Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med 174:1511–1515PubMedCrossRef

23.

Naume B, Espevik T (1991) Effects of IL-7 and IL-2 on highly enriched CD56+ natural killer cells. A comparative study. J Immunol 147:2208–2214PubMed

24.

Andersson A, Yang SC, Huang M, Zhu L, Kar UK, Batra RK, Elashoff D, Strieter RM, Dubinett SM, Sharma S (2009) IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol 182:6951–6958PubMedCrossRef

25.

Schroten-Loef C, de Ridder CM, Reneman S, Crezee M, Dalgleish A, Todryk SM, Bangma CH, Kraaij R (2009) A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intra-prostatic efficacy. Cancer Immunol Immunother 58:373–381PubMedCrossRef

26.

Di Carlo E, D’Antuono T, Pompa P, Giuliani R, Rosini S, Stuppia L, Musiani P, Sorrentino C (2009) The lack of epithelial interleukin-7 and BAFF/BLyS gene expression in prostate cancer as a possible mechanism of tumor escape from immunosurveillance. Clin Cancer Res 15:2979–2987PubMedCrossRef

27.

Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J, Jenster G (2006) Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 66:5012–5020PubMedCrossRef

28.

van der Heul-Nieuwenhuijsen L, Dits NF, Jenster G (2009) Gene expression of forkhead transcription factors in the normal and diseased human prostate. BJU Int 103:1574–1580PubMedCrossRef

29.

Rao AR, Motiwala HG, Karim OM (2008) The discovery of prostate-specific antigen. BJU Int 101:5–10PubMedCrossRef

30.

Shariat SF, Walz J, Roehrborn CG, Zlotta AR, Perrotte P, Suardi N, Saad F, Karakiewicz PI (2008) External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol 26:1526–1531PubMedCrossRef

31.

Svatek RS, Jeldres C, Karakiewicz PI, Suardi N, Walz J, Roehrborn CG, Montorsi F, Slawin KM, Shariat SF (2009) Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 69:886–894PubMedCrossRef

32.

Perry KT, Anthony CT, Case T, Steiner MS (1997) Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology 49:151–155PubMedCrossRef

33.

Mitropoulos D, Kiroudi A, Christelli E, Serafetinidis E, Zervas A, Anastasiou I, Dimopoulos C (2004) Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue. Urol Res 32:317–322PubMedCrossRef

34.

Lin Y, Nakachi K, Ito Y, Kikuchi S, Tamakoshi A, Yagyu K, Watanabe Y, Inaba Y, Kazuo T (2009) Variations in serum transforming growth factor-beta1 levels with gender, age and lifestyle factors of healthy Japanese adults. Dis Markers 27:23–28PubMed

35.

Porreca E, Di Febbo C, Vitacolonna E, Baccante G, Di Castelnuovo A, Angelini A, Febo F, Di Nisio M, Cuccurullo F (2002) Transforming growth factor-beta1 levels in hypertensive patients: association with body mass index and leptin. Am J Hypertens 15:759–765PubMedCrossRef

36.

Vudattu NK, Magalhaes I, Schmidt M, Seyfert-Margolis V, Maeurer MJ (2007) Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer. Int J Cancer 121:1512–1519PubMedCrossRef

37.

Hull GW, McCurdy MA, Nasu Y, Bangma CH, Yang G, Shimura S, Lee HM, Wang J, Albani J, Ebara S, Sato T, Timme TL, Thompson TC (2000) Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7–1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin Cancer Res 6:4101–4109PubMed

38.

Selleck WA, Canfield SE, Hassen WA, Meseck M, Kuzmin AI, Eisensmith RC, Chen SH, Hall SJ (2003) IFN-gamma sensitization of prostate cancer cells to Fas-mediated death: a gene therapy approach. Mol Ther 7:185–192PubMedCrossRef

39.

Steyerberg EW (2009) Clinical prediction models: a practical approach to development, validation, and updating. Springer, New York

Title: The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression
Authors: Caroline Schroten
Natasja F. Dits
Ewout W. Steyerberg
Ries Kranse
Arno G. J. L. H. van Leenders
Chris H. Bangma
Robert Kraaij
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 6/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-011-1159-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2012

Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate “Natural” and “Inducible” CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer

Regulatory T cells increase in breast cancer and in stage IV breast cancer

Tumor microenvironment and lymphocyte infiltration

Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria

Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients

Expression of antigen processing and presenting molecules in brain metastasis of breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer